Skip to content

Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

SMA Natural History Study Evaluating Long Term Trajectories of SMA Patients Receiving or Not Disease-modifying Treatments

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05768048
Enrollment
500
Registered
2023-03-14
Start date
2022-11-28
Completion date
2027-11-27
Last updated
2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Muscular Atrophy

Brief summary

This is an observational multicenter retrospective and prospective study on natural history of SMA also considering the 'new natural history' secondary to the availability of commercially available therapies. All the patients enrolled to date in the Italian registry, if not part of clinical trials, will be included in the present study.

Detailed description

This is an observational multicenter retrospective and prospective study on natural history of SMA also considering the 'new natural history' secondary to the availability of commercially available therapies. All patients affected by Spinal Muscular Atrophy 5q, irrespective of genotype, phenotype, age, treatment status or gender will be enrolled in the study . The study aims to i) better understand the natural history of the disease in untreated patients in terms of functional aspects, concomitant illnesses, quality of life ii) describe the patterns of disease progression in treated and untreated patients in terms of functional aspects, concomitant illnesses, quality of life iii) Describe all the patients treated with the available therapies in Italy, in terms of demographic (age, location etc..) and epidemiological data All data from patients included in the study will be collected at each visit, following the clinical care protocols of each centre. Following care recommendation patients are generally routinely assessed at least every 6 months and, in many cases, every 4 months. We plan to obtain * Longitudinal changes in untreated patients: The possibility to access reliable retrospective data will provide the opportunity to record long term functional data in untreated patients. * Yearly analysis of longitudinal changes in treated patients: * Two-year results of the validation of new measures (SMA HI, SMAIS): reporting the validation process (inter- and intra-observer reliability, internal consistency) and changes in relation to functional measures

Interventions

None listed

Sponsors

University of Milan
CollaboratorOTHER
Bambino Gesù Hospital and Research Institute
CollaboratorOTHER
University of Messina
CollaboratorOTHER
Gaslini Children's Hospital
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

all patients with mutationsin the SMAN1 gene

Exclusion criteria

unable to proviude consent

Design outcomes

Primary

MeasureTime frameDescription
motor function using the HFMSE (min score 0, max 74 indicating best performance)5 yearsmotor scale

Countries

Italy

Contacts

Primary ContactEugenio Mercuri, MD
eugeniomaria.mercuri@policlinicogemelli.it063015

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026